NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028
TABLE OF CONTENTS
1. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY
OUTLOOK
5.1. UNITED
STATES
5.2. CANADA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
LIST
TABLE 1: NORTH AMERICA ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $
MILLION)
TABLE 2: MARKET ATTRACTIVENESS
MATRIX
TABLE 3: VENDOR SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
FIGURE
LIST
FIGURE 1: PORTER’S FIVE FORCES
ANALYSIS
FIGURE 2: KEY IMPACT ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY COMPONENTS
FIGURE 5: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028
(IN $ MILLION)
FIGURE 11: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $
MILLION)
FIGURE 13: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 &
2028 (IN %)
FIGURE 14: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021
& 2028 (IN %)
FIGURE 17: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN
$ MILLION)
FIGURE 18: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028
(IN $ MILLION)
FIGURE 20: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $
MILLION)
FIGURE 22: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $
MILLION)
FIGURE 24: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
& 2028 (IN %)
FIGURE 25: UNITED STATES
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: CANADA ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
Rising elderly populace
to drive the AD therapeutics and diagnostics market growth in the region.
MARKET OUTLOOK
According to Triton
Market Research, the Alzheimer’s disease therapeutics and diagnostics market in
North America is estimated to grow with a CAGR of 6.82% over the forecast period
from 2022 to 2028. The United States and Canada are evaluated in the
market in this region.
The United States accounts
for the leading share in the AD therapeutics and diagnostics market. Data from
the National Institutes of Health (NIH) suggests that, nearly 5.8 million
Americans were affected by Alzheimer’s disease as of 2020. Of these, approximately
5.6 million people were in the age group of 65 years or more.
Also, according to data
from the US Census Bureau, the population of Americans aged 65 or older is likely
to reach 88 million individuals by 2050. As the number of elderly people in the
country continues to increase, the cases of Alzheimer’s will also spiral. This
will enhance the demand for therapeutics and diagnostics for AD, and thus contribute
to the growth of the US market.
The United States’ Food
and Drug Administration has approved 4 molecules, namely, galantamine,
memantine, rivastigmine, and donepezil, for Alzheimer’s disease treatment. Further,
as per the National Clinical Trials Registry (NCT), there are 144 Alzheimer’s
disease-associated clinical trials in the country currently ongoing across
different phases. Such active efforts by authorities are expected to steer the
market’s growth.
Get more insights the North America Alzheimer’s Disease Therapeutics And
Diagnostic Market:
COMPETITIVE OUTLOOK
The acclaimed players
in the Alzheimer’s disease therapeutics and diagnostics market are Zydus
Cadila, Baxter International Inc, Merck and Co, Eisai Co Ltd, Amarantus
Bioscience Holdings Inc, Allergan Plc (acquired by Abbvie), Cognoptix Inc, GE
Healthcare, and Sun Pharmaceuticals Industries Ltd.
SEGMENTATION
1. BAXTER
INTERNATIONAL INC
2. F.
HOFFMANN-LA ROCHE AG
3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
4. NOVARTIS
AG
5. PFIZER
INC
6. SIEMENS
HEALTHINEERS AG
7. AMARANTUS
BIOSCIENCE HOLDINGS INC
8. EISAI
CO LTD
9. ELI
LILLY & COMPANY
10. LUPIN
LIMITED
11. MERCK
AND CO
12. BIOGEN
INC
13. COGNOPTIX
INC
14. GE
HEALTHCARE
15. JOHNSON
AND JOHNSON
16. SUN
PHARMACEUTICALS INDUSTRIES LTD
17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
18. ZYDUS
CADILA
Comments
Post a Comment